Trail­blaz­ers, icon­o­clasts and break­through artists are com­ing to the End­points biotech sum­mit — please join us

Aviv Regev

When Aviv Regev closed out one long chap­ter of her life at the Broad and stepped in­to a new job as head of re­search and ear­ly de­vel­op­ment at Genen­tech four years ago, she set out to build a whole new ap­proach to drug dis­cov­ery on top of the broad base that had been in place for decades. Work­ing with new AI and ma­chine learn­ing tools pi­o­neered at the Broad, she’s been look­ing to blaze a new path in drug cre­ation in search of the holy grail of the R&D world: A high­er rate of sig­nif­i­cant suc­cess in the face of bleak — and ex­pen­sive — his­tor­i­cal re­al­i­ty.

Regev and I have had a chance to dis­cuss this a few times along the way in her jour­ney. And now we’ll be on stage at our par­al­lel BIO event in San Diego in a few weeks to ex­plore more about the most im­por­tant is­sues dri­ving the dis­cus­sion in the multi­bil­lion-dol­lar R&D in­dus­try, which is grap­pling with a trans­for­ma­tion­al tech­nol­o­gy.

Ja­mi Ru­bin

She’s one in a long line­up of top bio­phar­ma ex­ecs com­ing to our an­nu­al biotech sum­mit. I’m par­tic­u­lar­ly hap­py to tell you that Ja­mi Ru­bin, per­haps the sin­gle most out­spo­ken biotech an­a­lyst of her time, now a biotech CFO, will be sit­ting down for a con­ver­sa­tion with Ex­ec­u­tive Ed­i­tor Drew Arm­strong. Some of the most suc­cess­ful biotech ex­ecs in the in­dus­try will al­so be join­ing us to dis­cuss what it is that sep­a­rates the win­ners from the losers in the wake of a tough two-year down­turn. And both An­drew Dunn and Am­ber Tong are steer­ing their own pan­els on gene ther­a­py and the un­cer­tain fu­ture ahead for Chi­na biotechs.

You can get the full agen­da here, along with a sign-up sheet for tick­ets to the event. In case you aren’t mak­ing the trip to BIO this year, we al­so of­fer free reg­is­tra­tion for sub­scribers who want to watch on­line.

I’ll be hang­ing around on site all day on June 3. As al­ways, I’d en­cour­age you to drop by and say hel­lo and tell me a lit­tle about what you are do­ing. I’ve met quite a few biotech folks along the way in the last 22 years, and it’s al­ways the face-to-face that left the most vivid im­pres­sions. You can al­so meet Arm­strong and oth­ers on the End­points staff. Drop me a line in the mean­time if you have any ques­tions.